How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.
Jennifer Lachey, insider at Keros Therapeutics

Jennifer Lachey Insider Information

Insider of Keros Therapeutics
Jennifer Lachey has served as our Chief Scientific Officer since June 2019, and was previously our Vice President of Biology and Pharmacology beginning in July 2016. Prior to joining Keros, Dr. Lachey served as a Senior Director at Seres Therapeutics and was a Senior Director of Preclinical Pharmacology at Ember Therapeutics.  Previously, Dr. Lachey was Associate Director of Preclinical Pharmacology at Acceleron Pharma.  Dr. Lachey received a B.Sc. in Biology from Indiana University, and a Ph.D. in Neurobiology from the University of Cincinnati. Dr. Lachey completed her post-doctoral training at Beth Israel Deaconess Medical Center.

What is Jennifer Lachey's net worth?

The estimated net worth of Jennifer Lachey is at least $3.16 million as of May 11th, 2022. Dr. Lachey owns 85,700 shares of Keros Therapeutics stock worth more than $3,159,759 as of May 22nd. This net worth approximation does not reflect any other investments that Dr. Lachey may own. Additionally, Dr. Lachey receives a salary of $604,740.00 as Insider at Keros Therapeutics. Learn More about Jennifer Lachey's net worth.

How old is Jennifer Lachey?

Dr. Lachey is currently 50 years old. There are 4 older executives and no younger executives at Keros Therapeutics. The oldest executive at Keros Therapeutics is Dr. Jasbir Seehra Ph.D., Pres, CEO, Treasurer, & Director, who is 66 years old. Learn More on Jennifer Lachey's age.

What is Jennifer Lachey's salary?

As the Insider of Keros Therapeutics, Inc., Dr. Lachey earned a total compensation package of $3,542,278.00 in 2020. Dr. Lachey earned a salary of $370,196.00, options awards of $3,017,362.00, non-equity compensation of $154,200.00, and other compensation of $521.00.The highest earning executive at Keros Therapeutics is Dr. Jasbir Seehra Ph.D., Pres, CEO, Treasurer, & Director, who commands a salary of $908,090.00 per year. Learn More on Jennifer Lachey's salary.

How do I contact Jennifer Lachey?

The corporate mailing address for Dr. Lachey and other Keros Therapeutics executives is 99 HAYDEN AVENUE SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER, LEXINGTON MA, 02421. Keros Therapeutics can also be reached via phone at 617-314-6297 and via email at [email protected] Learn More on Jennifer Lachey's contact information.

Has Jennifer Lachey been buying or selling shares of Keros Therapeutics?

During the past quarter, Jennifer Lachey has sold $1,031,751.00 in Keros Therapeutics stock. 0 shares of the firm's stock in a transaction on Sunday, May 22nd. Learn More on Jennifer Lachey's trading history.

Who are Keros Therapeutics' active insiders?

Keros Therapeutics' insider roster includes Julius Knowles (Director), and Jennifer Lachey (Insider). Learn More on Keros Therapeutics' active insiders.

Are insiders buying or selling shares of Keros Therapeutics?

During the last year, insiders at the sold shares 26 times. They sold a total of 300,396 shares worth more than $13,865,091.58. The most recent insider tranaction occured on May, 11th when insider Jennifer Lachey sold 5,300 shares worth more than $222,070.00. Insiders at Keros Therapeutics own 36.1 % of the company. Learn More about insider trades at Keros Therapeutics.

Information on this page was last updated on 5/11/2022.

Jennifer Lachey Insider Trading History at Keros Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2022Sell5,300$41.90$222,070.0085,700View SEC Filing Icon  
4/11/2022Sell5,300$62.77$332,681.0085,700View SEC Filing Icon  
4/4/2022Sell7,950$60.00$477,000.0085,700View SEC Filing Icon  
3/11/2022Sell2,650$53.38$141,457.00View SEC Filing Icon  
2/11/2022Sell2,650$52.06$137,959.00View SEC Filing Icon  
1/11/2022Sell2,650$53.75$142,437.50View SEC Filing Icon  
1/5/2022Sell2,650$60.00$159,000.00View SEC Filing Icon  
12/15/2021Sell735$50.00$36,750.00View SEC Filing Icon  
12/13/2021Sell1,915$50.55$96,803.25View SEC Filing Icon  
11/10/2021Sell15,900$60.00$954,000.00View SEC Filing Icon  
6/11/2021Sell2,650$50.98$135,097.001,000View SEC Filing Icon  
See Full Table

Jennifer Lachey Buying and Selling Activity at Keros Therapeutics

This chart shows Jennifer Lachey's buying and selling at Keros Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Keros Therapeutics Company Overview

Keros Therapeutics logo
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Read More

Today's Range

Now: $36.87
Low: $35.52
High: $38.25

50 Day Range

MA: $54.19
Low: $36.13
High: $67.04

2 Week Range

Now: $36.87
Low: $28.50
High: $68.29

Volume

199,620 shs

Average Volume

193,502 shs

Market Capitalization

$885.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11
How You Should Be Choosing Your Stocks
Grab your seat at our complimentary LIVE, interactive masterclass for traders. It’s your chance to finally learn how to pick the right stocks and find the best trades. We’ll also be diving into market forecasting and revealing under-the-radar stocks we believe have significant potential in Q2.
Click here now to join and get access to our forecasting.